Omnicell Inc. (NASDAQ:OMCL) traded down 2.6% during trading on Thursday . The company traded as low as $35.81 and last traded at $35.83, with a volume of 62,522 shares. The stock had previously closed at $36.77.

A number of equities research analysts have commented on the stock. Zacks Investment Research upgraded shares of Omnicell from a “hold” rating to a “strong-buy” rating and set a $41.00 price target for the company in a report on Monday. FBR & Co raised their price target on shares of Omnicell from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Thursday, July 7th. Finally, Topeka Capital Markets reduced their price target on shares of Omnicell from $38.00 to $37.00 and set a “buy” rating for the company in a report on Monday, March 21st. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $37.25.

The firm’s 50-day moving average price is $33.89 and its 200-day moving average price is $29.83. The stock has a market cap of $1.29 billion and a P/E ratio of 54.08.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, April 28th. The company reported $0.35 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.09. The business earned $171 million during the quarter, compared to the consensus estimate of $167.18 million. Omnicell’s revenue for the quarter was up 47.1% on a year-over-year basis. During the same quarter last year, the company earned $0.29 EPS. On average, equities research analysts predict that Omnicell Inc. will post $1.56 EPS for the current fiscal year.

In other Omnicell news, VP Jorge R. Taborga sold 1,933 shares of the firm’s stock in a transaction that occurred on Friday, May 20th. The shares were sold at an average price of $30.73, for a total transaction of $59,401.09. Following the sale, the vice president now owns 52,667 shares in the company, valued at approximately $1,618,456.91. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Sara J. White sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 5th. The stock was sold at an average price of $31.76, for a total transaction of $63,520.00. Following the sale, the director now owns 40,433 shares in the company, valued at approximately $1,284,152.08. The disclosure for this sale can be found here.

A number of large investors have recently added to or reduced their stakes in OMCL. State Board of Administration of Florida Retirement System boosted its stake in Omnicell by 10.4% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 42,213 shares of the company’s stock worth $1,312,000 after buying an additional 3,982 shares during the last quarter. Rhumbline Advisers boosted its stake in Omnicell by 1.4% in the fourth quarter. Rhumbline Advisers now owns 45,301 shares of the company’s stock worth $1,408,000 after buying an additional 620 shares during the last quarter. Comerica Bank boosted its stake in Omnicell by 8.9% in the fourth quarter. Comerica Bank now owns 68,602 shares of the company’s stock worth $1,885,000 after buying an additional 5,629 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Omnicell by 10.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 93,675 shares of the company’s stock worth $2,910,000 after buying an additional 9,066 shares during the last quarter. Finally, Eagle Asset Management Inc. boosted its stake in Omnicell by 61.7% in the fourth quarter. Eagle Asset Management Inc. now owns 145,971 shares of the company’s stock worth $4,536,000 after buying an additional 55,678 shares during the last quarter.

Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.